Evaluation of Diagnostic Methods and Rifampicin Resistance in Pulmonary Tuberculosis: A Hospital-Based Study
- PMID: 39286711
- PMCID: PMC11403642
- DOI: 10.7759/cureus.67062
Evaluation of Diagnostic Methods and Rifampicin Resistance in Pulmonary Tuberculosis: A Hospital-Based Study
Abstract
Background Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, predominantly affecting the lungs (pulmonary TB) and is a significant public health challenge in India. The study aims to analyze demographic, radiological, and clinical subgroups of pulmonary TB cases, examine the relationship between smear acid-fast bacillus (AFB examination) and cartridge-based nucleic acid amplification test (CBNAAT), evaluate CBNAAT sensitivity for Mycobacterium tuberculosis (MTB) in new and previously treated patients, and determine the proportion of rifampicin resistance. Methods This hospital-based prospective study was conducted among patients diagnosed with pulmonary TB at the Respiratory Medicine Department of a Government Hospital over 16 months (August 2019 to December 2020). The study included 150 diagnosed TB cases (new and previously treated). Data collection encompassed demographic details, clinical symptoms, comorbidities, radiological findings (chest X-ray), and microbiological results (smear AFB examination, CBNAAT). Sputum samples were subjected to Ziehl-Neelsen staining and CBNAAT for MTB detection and rifampicin resistance testing. Statistical analysis was performed using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY, USA). Results Of the 150 patients, 69.3% were male, and 48% were aged 21-40 years. The majority had a BMI of 18.5-24.9 kg/m² (50%) and resided in urban areas (63.3%). Common symptoms included cough (95.3%), fever (80%), and weight loss (74%). Cavitary lesions on chest X-ray were observed in 84% of patients. Smear microscopy detected MTB in 72.7% of cases, while CBNAAT detected MTB in 94% of cases. CBNAAT sensitivity for smear-positive and smear-negative samples was 93.97% and 94.12%, respectively. Rifampicin resistance was found in 3% of new cases and 6% of previously treated cases. The sensitivity of smear microscopy was 77.33%, and the sensitivity of CBNAAT was 94%. Conclusion The study underscores the high burden of pulmonary TB and the utility of CBNAAT in detecting MTB and rifampicin resistance, particularly in smear-negative samples. The findings highlight the necessity of universal drug susceptibility testing (DST) for effective TB management and the importance of addressing drug resistance to improve treatment outcomes.
Keywords: cbnaat; drug-resistant tuberculosis; rifampicin resistance; sensitivity; smear afb examination.
Copyright © 2024, Joshi et al.
Conflict of interest statement
Human subjects: Consent was obtained or waived by all participants in this study. Mahaveer Institute of Medical Sciences and Research issued approval MIMSR/IEC/2018/6/006. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Similar articles
-
Detection of drug-resistant Mycobacterium tuberculosis in pericardial fluid culture and its correlation with cartridge based nucleic acid amplification test and adenosine deaminase activity.Indian J Tuberc. 2024;71 Suppl 1:S59-S66. doi: 10.1016/j.ijtb.2023.09.014. Epub 2023 Sep 29. Indian J Tuberc. 2024. PMID: 39067957
-
Comparison of conventional diagnostic methods with molecular method for the diagnosis of pulmonary tuberculosis.Indian J Tuberc. 2023 Apr;70(2):182-189. doi: 10.1016/j.ijtb.2022.04.006. Epub 2022 May 4. Indian J Tuberc. 2023. PMID: 37100575
-
Impact of cartridge-based nucleic acid amplification test (CBNAAT) introduction on the detection of pulmonary and extra-pulmonary tuberculosis in Bhubaneswar, Odisha.Indian J Pathol Microbiol. 2023 Oct-Dec;66(4):764-769. doi: 10.4103/ijpm.ijpm_666_22. Indian J Pathol Microbiol. 2023. PMID: 38084529
-
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.Cochrane Database Syst Rev. 2019 Jun 7;6(6):CD009593. doi: 10.1002/14651858.CD009593.pub4. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2021 Feb 22;2:CD009593. doi: 10.1002/14651858.CD009593.pub5. PMID: 31173647 Free PMC article. Updated.
-
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD013359. doi: 10.1002/14651858.CD013359.pub2. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2022 Sep 6;9:CD013359. doi: 10.1002/14651858.CD013359.pub3. PMID: 32853411 Free PMC article. Updated.
References
-
- Evaluation of the Xpert MTB/RIF Assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Theron G, Peter J, van Zyl-Smit RV, et al. Am J Respir Crit Care Med. 2011;184:132–140. - PubMed
LinkOut - more resources
Full Text Sources